We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Urovant Sciences Ltd. (“Urovant” or the “Company”) (NASDAQ: UROV) to Sumitovant Biopharma (“Sumitovant”). Sumitovant currently owns 72% of the outstanding shares of Urovant common stock, and under the terms of the merger agreement, will acquire the outstanding shares of Urovant common stock it does not already own at a price of $16.25 per share in cash.
The Urovant merger investigation concerns whether the Board of Urovant has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.